Kathy Johnson Weiler Sells 14,150 Shares of AxoGen (NASDAQ:AXGN) Stock

AxoGen, Inc. (NASDAQ:AXGN) Director Kathy Johnson Weiler sold 14,150 shares of the company’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $45.30, for a total transaction of $640,995.00. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

AxoGen Trading Up 2.5%

Shares of NASDAQ:AXGN opened at $49.67 on Thursday. The company has a market cap of $2.67 billion, a P/E ratio of -73.04 and a beta of 1.11. The stock’s 50-day moving average is $43.19 and its 200-day moving average is $38.27. AxoGen, Inc. has a 52-week low of $13.64 and a 52-week high of $49.90. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.04 and a current ratio of 6.60.

AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, July 29th. The medical equipment provider reported $0.12 EPS for the quarter, hitting analysts’ consensus estimates of $0.12. AxoGen had a negative return on equity of 8.90% and a negative net margin of 13.36%.The business had revenue of $69.73 million for the quarter, compared to analyst estimates of $67.10 million. Equities research analysts predict that AxoGen, Inc. will post -0.45 earnings per share for the current year.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of AxoGen in a research report on Friday, May 29th. HC Wainwright upped their target price on shares of AxoGen from $50.00 to $53.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Raymond James Financial restated an “outperform” rating and issued a $48.00 price target on shares of AxoGen in a research report on Wednesday, April 29th. Citigroup restated a “market outperform” rating on shares of AxoGen in a report on Thursday, July 30th. Finally, Lake Street Capital upped their price objective on shares of AxoGen from $40.00 to $50.00 and gave the company a “buy” rating in a research report on Thursday, April 23rd. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $51.00.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently bought and sold shares of AXGN. MCF Advisors LLC bought a new stake in AxoGen in the 4th quarter valued at $30,000. Aquatic Capital Management LLC lifted its holdings in shares of AxoGen by 287.8% during the 3rd quarter. Aquatic Capital Management LLC now owns 1,710 shares of the medical equipment provider’s stock worth $31,000 after acquiring an additional 1,269 shares during the period. Arax Advisory Partners boosted its position in shares of AxoGen by 362.4% during the 4th quarter. Arax Advisory Partners now owns 1,045 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 819 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of AxoGen during the 4th quarter valued at about $36,000. Finally, Kestra Advisory Services LLC bought a new stake in AxoGen in the fourth quarter valued at about $39,000. 80.29% of the stock is owned by institutional investors.

About AxoGen

AxoGen, Inc is a Florida-based medical technology company that develops and commercializes surgical solutions for peripheral nerve damage. Founded in 2002 and headquartered in Alachua, Florida, the company focuses on restoring nerve function and improving patient outcomes through innovative biologic and engineered products. AxoGen’s offerings address a range of traumatic and iatrogenic injuries, offering alternatives to traditional nerve autografts.

The company’s core product portfolio includes the Avance® Nerve Graft, a decellularized human nerve allograft designed to bridge nerve gaps without the need for a secondary harvest site, and the Axoguard® Nerve Connector and Protector devices, which facilitate nerve coaptation and protect repaired sites from surrounding scar tissue.